CYP4A11 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL154857	0.50	7/20
SCHEMBL46931	1.00	6/20
SCHEMBL154855	0.57	6/20
SCHEMBL77965	0.56	5/20
SCHEMBL158414	0.52	5/20
SCHEMBL154856	0.51	5/20
SCHEMBL220706	0.38	5/20
SCHEMBL63871	0.37	5/20
SCHEMBL122682	0.67	4/20
SCHEMBL186122	0.64	4/20
SCHEMBL80185	0.58	4/20
SCHEMBL46332	0.53	4/20
SCHEMBL40656	0.52	4/20
SCHEMBL96188	0.51	4/20
SCHEMBL186370	0.51	4/20
SCHEMBL187373	0.51	4/20
SCHEMBL20413	0.50	4/20
SCHEMBL168858	0.49	4/20
SCHEMBL77237	0.47	4/20
SCHEMBL127411	0.46	4/20

Clinical trials — most relevant to CYP4A11 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity	PHASE4	COMPLETED
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies	PHASE4	RECRUITING
A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)	PHASE3	NOT_YET_RECRUITING
A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia	PHASE3	NOT_YET_RECRUITING
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer	PHASE2	RECRUITING
Androgen Reduction in Congenital Adrenal Hyperplasia	PHASE2	WITHDRAWN
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis	PHASE2	RECRUITING
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer	PHASE2	COMPLETED
Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA)	PHASE2	COMPLETED
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma	PHASE2	NOT_YET_RECRUITING
Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas	PHASE2	COMPLETED
Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects	PHASE1	NOT_YET_RECRUITING
A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer	PHASE1	RECRUITING
A Phase I Trial of QLS1410 in Healthy Chinese Adults and Participants With Mild Essential Hypertension	PHASE1	NOT_YET_RECRUITING
A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease	PHASE1	COMPLETED
Alcohol Inhibits Drug Metabolism by Carboxylesterases	PHASE1	COMPLETED
Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma	PHASE1	COMPLETED
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies	PHASE1	COMPLETED
Cholesterol Metabolites as Markers for CYP3A Induction	nan	COMPLETED
Connecting Breath and Mind for CYP With Long COVID	nan	UNKNOWN
Cholesterol and CYP3A4/5 Metabolism Across Pregnancy and Postpartum	nan	COMPLETED
The Texas Interprofessional Pharmacogenomics (IPGx)	nan	RECRUITING
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer	nan	COMPLETED
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients	nan	COMPLETED
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages	nan	COMPLETED
A Prospective Observational Study of Biomarkers for a Personalised IVF Treatment	nan	UNKNOWN
Involvement of Pollutants in Atopic Dermatitis and Psoriasis	nan	UNKNOWN
CYP2D6 Genotyping by AmpliChipTM CYP450 for Tamoxifen-Treated Breast Cancer Patients	nan	UNKNOWN
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CYP4A11 binder may also engage these)

Protein	Name	Similarity
P14580	—	0.998	P14580 →
Q8SPK0	—	0.998	Q8SPK0 →
Q9GJX5	—	0.997	Q9GJX5 →
CYP4A22	Cytochrome P450 4A22 (CYPIVA22) (Fatty acid o	0.996	landscape →
P14579	—	0.996	P14579 →
P10611	—	0.993	P10611 →
P14581	—	0.991	P14581 →
Q8SPK1	—	0.985	Q8SPK1 →
CYP46A1	Cholesterol 24-hydroxylase	0.982	landscape →
Q9WVK8	—	0.982	Q9WVK8 →
O35728	—	0.975	O35728 →
O77809	—	0.971	O77809 →
CYP4B1	Cytochrome P450 4B1 (EC 1.14.14.1) (CYPIVB1)	0.968	landscape →
P30099	—	0.968	P30099 →
P30100	—	0.967	P30100 →
P15150	—	0.967	P15150 →
O93297	—	0.966	O93297 →
P24464	—	0.965	P24464 →
P20817	—	0.965	P20817 →
P15539	—	0.964	P15539 →
Q64658	—	0.964	Q64658 →
CYP1A2	Cytochrome P450 1A2	0.964	landscape →
Q5KQT6	—	0.963	Q5KQT6 →
Q4H4C3	—	0.963	Q4H4C3 →
O93299	—	0.963	O93299 →
Q29552	—	0.963	Q29552 →
A2A974	—	0.963	A2A974 →
P20816	—	0.961	P20816 →
Q92090	—	0.960	Q92090 →
P00185	—	0.960	P00185 →